HalioDx Signs an Agreement with Everything Genetic to Make Immunoscore® Colon Assay Available in the UK
HalioDx SAS, an immuno-oncology diagnostic company, announced that Everything Genetic Ltd. will market and distribute Immunoscore® Colon assay in the United Kingdom.
Oncologists and patients in the UK will have access to Immunoscore® Colon, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer. Immunoscore® Colon combines tissue diagnostic and advanced image analysis technologies to quantify T-cells which infiltrate both the core of the colon tumor and its invasive margin. The assay guides oncologists to decide on critical therapeutic options in stages II and stage III colon cancers[1]. It is the very first IVD assay of the HalioDx Immunoscore® pipeline, leveraging image analysis technology to enhance clinical utility and standardization.
“There are 30 000 new cases of Colon Cancer per year in the UK[2] . For half of these patients, treatment decisions are problematic leading to over or under treatments. Thanks to Immunoscore® Colon, relapse risk assessment will be improved for these patients,” says Vincent Fert CEO of HalioDx. He added “We are delighted to collaborate with Everything Genetic Ltd., an expert company enabling UK oncologists and patients to access value-based diagnostic solutions.”
James Price, CEO of Everything Genetic Ltd, the distributor of HalioDx’s products in the UK, comments: “We are delighted to be working with HalioDx to provide its diagnostics tests across the UK. By providing easy access to these tests, our collaboration offers value for money and gives patients and physicians the power to make the best possible therapeutic decisions. Reimbursement for innovative genetic profiling diagnostics tools is growing and we look forward to building on our partnership with HalioDx to expand the offering of precision medicine tools in the UK”.
Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study[3] conducted on more than 2600 patients have been published in The Lancet journal. The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147[4] study.
[1] Hermitte J Immunother Cancer 2016
[2] Source: Cancer Research UK
[3] Pagès et al. The Lancet 2018
[4] Sinicrope et al. Oral presentation ASCO GI 2018
Source: HalioDx
